Stock Report

All about this stock under one free report Last Updated: 28-Aug-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Vertex Pharmaceuticals (VRTX) Peer Comparison

Stock Card factsheet share-fund-plan-icon

$547.55

up-down-arrow $0.26 (0.05%)

As on 27-Aug-2026 16:18EDT

Market cap

info icon

$138,909 Mln

Revenue (TTM)

info icon

$12,624 Mln

P/E Ratio

info icon

31.4

P/B Ratio

info icon

6.8

Div. Yield

info icon

0 %

Edit peer-selector-edit
Vertex Pharmaceuticals (VRTX) Regeneron Pharmaceuticals (REGN) Revolution Medicines (RVMD) IQVIA Holdings (IQV) Alnylam Pharmaceuticals (ALNY)
Market cap ($ Mln)
 138,909 85,869 44,895 42,612 31,608
Revenue ($ Mln)
 12,624 15,535 -- 16,983 4,804
Net Profit ($ Mln)
 4,405.20 4,328.70 -1,768.29 1,375.00 807.99
Net Margin (%)
 34.89 27.86 -- 8.10 16.82
RoE (%)
 22.64 13.75 -83.46 21.63 75.40
Price to Earnings
 31.44 20.45 -- 32.20 39.97
Price-To-Book
 6.76 2.68 17.41 6.65 22.66

Income Statement ($ Mln)

Vertex Pharmaceuticals (VRTX) Regeneron Pharmaceuticals (REGN) Revolution Medicines (RVMD) IQVIA Holdings (IQV) Alnylam Pharmaceuticals (ALNY)
Operating Revenue arrow
12,624.30 15,534.70 0.00 16,983.00 4,804.18
Cost of Revenue arrow
1,762.80 2,352.10 9.24 12,528.00 974.34
Gross Profit arrow
10,267.50 12,242.20 -16.56 4,286.00 3,036.77
Operating Expenses arrow
5,989.90 9,212.50 1,618.01 2,150.00 2,830.07
Operating Profit (EBIT) arrow
4,872.00 3,970.10 -1,627.25 2,305.00 999.78
Other Income arrow
0.00 0.00 0.00 0.00 0.00
Profit before Tax arrow
5,274.90 5,166.00 -1,768.29 1,609.00 799.57
Provision for Tax arrow
869.30 837.30 0.00 253.00 -39.75
Profit after Tax (Net Income) arrow
4,405.20 4,328.70 -1,768.29 1,375.00 807.99
Minority Interest arrow
0.00 0.00 0.00 -4.00 0.00
Consolidated Profit arrow
0.00 0.00 0.00 845.00 0.00

Liabilities ($ Mln)

Vertex Pharmaceuticals (VRTX) Regeneron Pharmaceuticals (REGN) Revolution Medicines (RVMD) IQVIA Holdings (IQV) Alnylam Pharmaceuticals (ALNY)
Shareholder's Funds arrow
20,247.90 31,711.00 2,606.24 6,171.00 1,354.12
Minority Interest arrow
0.00 0.00 0.00 -4.00 0.00
Non-Current Liabilities arrow
3,237.50 4,488.60 1,362.97 14,765.00 2,692.14
Current Liabilities arrow
3,937.90 5,530.60 354.06 8,815.00 1,512.51
Total Liabilities arrow
26,142.80 40,558.70 2,354.51 29,944.00 4,966.33

Assets ($ Mln)

Vertex Pharmaceuticals (VRTX) Regeneron Pharmaceuticals (REGN) Revolution Medicines (RVMD) IQVIA Holdings (IQV) Alnylam Pharmaceuticals (ALNY)
Non-Current Assets arrow
14,879.60 23,284.00 294.93 23,655.00 938.60
Current Assets arrow
12,543.70 18,446.00 4,028.34 6,226.00 4,620.17
Total Assets arrow
26,142.80 40,558.70 2,354.51 29,944.00 4,966.33
Total Debt* arrow
1,977.60 1,986.60 641.93 16,241.00 1,267.41
Net Current Assets arrow
8,605.80 12,915.40 3,674.28 -2,589.00 3,107.66

Cashflow ($ Mln)

Vertex Pharmaceuticals (VRTX) Regeneron Pharmaceuticals (REGN) Revolution Medicines (RVMD) IQVIA Holdings (IQV) Alnylam Pharmaceuticals (ALNY)
Cash From Operating Activities arrow
3,631.40 4,978.90 -897.74 2,654.00 524.08
Cash Flow from Investing Activities arrow
-945.40 -629.10 118.06 -2,305.00 436.33
Cash from Financing Activities arrow
-2,261.30 -3,715.40 621.52 -150.00 -305.19
Net Cash Inflow / Outflow arrow
-- -- -- -- --

Ratios

Profitability Ratios

 Vertex Pharmaceuticals (VRTX) Regeneron Pharmaceuticals (REGN) Revolution Medicines (RVMD) IQVIA Holdings (IQV) Alnylam Pharmaceuticals (ALNY)
ROCE (%) arrow
19.42 13.65 -53.99 6.34 18.29
ROE (%) arrow
22.64 13.75 -83.46 21.63 75.40
ROA (%) arrow
14.80 9.71 -48.50 3.67 12.49
EBIT Margin (%) arrow
41.83 33.61 -- 13.81 22.81
Net Margin (%) arrow
34.89 27.86 -- 8.10 16.82
Cash Profit Margin (%) arrow
0.00 0.00 -- 0.00 0.00

Growth Ratios

 Vertex Pharmaceuticals (VRTX) Regeneron Pharmaceuticals (REGN) Revolution Medicines (RVMD) IQVIA Holdings (IQV) Alnylam Pharmaceuticals (ALNY)
Revenue Growth (%) arrow
10.56 9.29 -- 8.17 95.14
EBIT Growth (%) arrow
20.31 6.31 -33.90 5.30 581.89
Net Profit Growth (%) arrow
21.10 -2.91 -117.75 11.16 353.22
EPS Growth (%) arrow
22.80 1.72 -95.21 16.60 337.57
Book Value Growth (%) arrow
19.36 7.70 24.65 9.72 406.86

Valuation Ratios

 Vertex Pharmaceuticals (VRTX) Regeneron Pharmaceuticals (REGN) Revolution Medicines (RVMD) IQVIA Holdings (IQV) Alnylam Pharmaceuticals (ALNY)
Price / Earnings arrow
29.37 18.42 -13.39 28.49 172.73
Price / Book Value arrow
6.22 2.65 9.28 5.96 68.67
Dividend Yield (%) arrow
-- -- -- -- --
EV/EBITDA arrow
23.31 13.25 -12.17 15.24 83.24
Market Cap ($ Cr) arrow
-- -- -- -- --

Solvency Ratios

 Vertex Pharmaceuticals (VRTX) Regeneron Pharmaceuticals (REGN) Revolution Medicines (RVMD) IQVIA Holdings (IQV) Alnylam Pharmaceuticals (ALNY)
Debt to Equity arrow
0.00 0.06 0.19 2.22 0.75
Short term debt to equity ratio arrow
0.00 0.00 0.01 0.37 0.03
Current Ratio arrow
3.19 3.34 11.38 0.71 3.05
Quick Ratio arrow
2.74 2.78 11.38 0.71 2.99
Interest Coverage arrow
800.23 94.25 -28.80 3.09 3.46

Operating Efficiency Ratios

 Vertex Pharmaceuticals (VRTX) Regeneron Pharmaceuticals (REGN) Revolution Medicines (RVMD) IQVIA Holdings (IQV) Alnylam Pharmaceuticals (ALNY)
Debtors to sales (%) arrow
16.91 42.26 -- 19.94 19.00
Asset Turnover arrow
0.42 0.35 0.00 0.45 0.74
Receivable days arrow
55.39 152.19 -- 74.65 58.17
Inventory Days arrow
292.28 546.66 -- -- 43.48
Payable days arrow
88.40 150.27 1,312.97 68.15 55.05
Cash Conversion Cycle arrow
259.28 548.59 -- -- 46.59
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...